ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

1:00PM-2:30PM: Abstract Number: 1650

IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

1:00PM-2:30PM: Abstract Number: 1657

Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1648

In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

1:00PM-2:30PM: Abstract Number: 1656

Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1665

Multicenter Randomized Controlled Trial of Physical Therapy (PT) or Sham PT in Persons with Knee Pain, Meniscal Tear, and Osteoarthritic Imaging Changes

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

1:00PM-2:30PM: Abstract Number: 1663

Notch—mediated Fibrogenic Activation Is a Spatial Determinant of RA Treatment Response

Abstracts: RA – Etiology and Pathogenesis I

1:00PM-2:30PM: Abstract Number: 1694

One-Year Survival Following Single versus Double Lung Transplantation in Adults with Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Disease: A Nationwide Cohort Study

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1653

Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1655

Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Target for Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1670

Predictors of 6-Minute Walk Test Performance in Adults with Arthritis

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

1:00PM-2:30PM: Abstract Number: 1666

Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

1:00PM-2:30PM: Abstract Number: 1689

Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1680

Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1697

Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1661

Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation

Abstracts: RA – Etiology and Pathogenesis I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].